Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
Rhea-AI Summary
Heron Therapeutics (Nasdaq: HRTX) has rescheduled its second quarter 2025 financial results release and conference call to Friday, August 8, 2025, at 8:30 a.m. ET, moved up from the previously scheduled date of August 11, 2025.
The company will discuss Q2 2025 financial results and recent business highlights during the call. Participants are encouraged to dial in fifteen minutes before the start time using the provided registration link. The presentation will also be available via webcast on Heron's website, with a replay accessible for 60 days following the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, HRTX declined 28.26%, reflecting a significant negative market reaction. Argus tracked a trough of -37.9% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $111M from the company's valuation, bringing the market cap to $281M at that time. Trading volume was exceptionally heavy at 15.9x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-reschedules-second-quarter-2025-earnings-release-and-conference-call-to-friday-august-8-2025-302525007.html
SOURCE Heron Therapeutics, Inc.
FAQ
When is Heron Therapeutics (HRTX) reporting Q2 2025 earnings?
How can investors access Heron Therapeutics' Q2 2025 earnings call?
How long will the replay of Heron Therapeutics' Q2 2025 earnings call be available?
Why did Heron Therapeutics reschedule its Q2 2025 earnings call?
